Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland

- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference -

TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ -- Abe Yoando Pharma Co., Ltd., a nearly 300-year-old pharmaceutical company headquartered in Tokyo and advancing longevity science, announced that its President Tomonari Abe has been selected as the first Japanese speaker (*1) to present at the Longevity Investors Conference 2026, to be held in Gstaad, Switzerland, from September 14 to 17, 2026.

Image: https://drive.google.com/file/d/1loBgPPyXeUUfvwbmmjQUIyxxQJ927XEB/view?usp=sharing 

As global interest in healthy longevity expands, the market is projected to reach approximately $8 trillion by 2030 (*2). Japan, facing an aging population ahead of other nations, is increasingly recognized by international investors and researchers as a pivotal region for longevity research and market validation. Awarded as one of the 20 finalist teams in the global XPRIZE Healthspan competition, Abe Yoando Pharma integrates centuries-old wellness traditions with modern biotechnology to advance scientific longevity initiatives.

At the conference, Abe will present on the theme: "The Longevity Opportunity in Asia: Building the Infrastructure for an Aging World."

"It is an honor to present Japan's potential to leading global investors," said Abe. "Japan's demographic landscape provides unique insights for longevity research. By combining nearly three centuries of traditional expertise with cutting-edge bioscience, we aim to demonstrate scalable, global growth strategies originating from Asia."

Abe Yoando Pharma remains focused on advancing research and development of high-purity nicotinamide mononucleotide (NMN) and conducting joint scientific studies with academic research institutions. Through international collaboration, the company aims to support global healthy aging initiatives through rigorous scientific inquiry into cellular mechanisms, including sirtuin genes.

About Abe Yoando Pharma Co., Ltd.
Founded in 1731 as official physicians to the shogun of the Matsudaira clan, Abe Yoando Pharma has evolved over nearly 300 years to advance health and longevity science. Combining heritage with modern biotechnology, the company pioneers NMN research and longevity science. Abe Yoando Pharma is among the 20 finalist teams selected out of 799 entries across 58 countries in the XPRIZE Healthspan competition.

Official website: https://corp.abeyoando.co.jp/?lang=en 

Notes & Reference Links
(*1) First Japanese speaker: Based on Abe Yoando Pharma's internal research as of September 2026, referencing the official speaker directory published by the Longevity Investors Conference since its inauguration.

(*2) Longevity market projection: Source: UBS Chief Investment Office (CIO) Research Report, "Investing in Longevity," published by UBS Group AG / UBS SuMi TRUST Wealth Management.

Reference URL: https://www.ubs-sumitrust.com/cio-research/report/6474 

SOURCE Abe Yoando Pharma Co., Ltd.